含呋喃唑酮治疗方案治疗一线治疗失败的幽门螺旋杆菌感染(2)
参考文献:
[1] Malfertheiner P, Megraud F, O'Morain C,et a1.Current concepts in the management of Helieobaeter pylori infection:the Maastricht III consensus report[J].Gut,2007,56(6):772-781.
[2] 中华医学会消化病学分会幽门螺杆菌学缈幽门螺杆菌科研协作组. 第三次全国幽门螺杆菌感染若干问题共识报告[J]. 中华医学杂志,2008,8(10):652-656.
[3] 成虹,胡伏莲,谢勇,等.中国幽门螺杆菌耐药状况以及耐药对治疗的影响一全国多中心临床研究[J].胃肠病学,2007,12(9):525-530.
[4] Song Z,Zhou L,W ang Y,et a1. A study to explore Hp antibiotic resistance and efficacy of eradication therapy in china (multi—center,nation—wide,randomized,control study) (abstract)[J].Helicobacter,2011,16 Suppl 1:117.
[5] Rimbara E, Fischbach LA, Graham DY, et al. Optimal therapy for Helicobacter pylori infections[J]. Gastroenterology & Hepatology, 2011, 8: 79-88.
[6] 萧树东,刘文忠,胡品律,等.短程三联疗法根除幽门螺旋杆菌的多中心临床研究[J].胃肠病学,2000,5(1):14-18.
[7] 刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].中华消化杂志,2012,32(10):655-661.
[8] M alfertheiner P, Megraud F, O ’Morain CA , et a1.Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Repoa[J].Gut,2012,61(5):646-664.
[9] Zullo A, Lerardi E, Hassan C, et al. Furazolidone-based therapies for Helicobacter pylori infection:A pooled date-analysis[J]. Saudi J Gastroenterol, 2012, 18:11-17., 百拇医药(李永宇 陈梅花)
[1] Malfertheiner P, Megraud F, O'Morain C,et a1.Current concepts in the management of Helieobaeter pylori infection:the Maastricht III consensus report[J].Gut,2007,56(6):772-781.
[2] 中华医学会消化病学分会幽门螺杆菌学缈幽门螺杆菌科研协作组. 第三次全国幽门螺杆菌感染若干问题共识报告[J]. 中华医学杂志,2008,8(10):652-656.
[3] 成虹,胡伏莲,谢勇,等.中国幽门螺杆菌耐药状况以及耐药对治疗的影响一全国多中心临床研究[J].胃肠病学,2007,12(9):525-530.
[4] Song Z,Zhou L,W ang Y,et a1. A study to explore Hp antibiotic resistance and efficacy of eradication therapy in china (multi—center,nation—wide,randomized,control study) (abstract)[J].Helicobacter,2011,16 Suppl 1:117.
[5] Rimbara E, Fischbach LA, Graham DY, et al. Optimal therapy for Helicobacter pylori infections[J]. Gastroenterology & Hepatology, 2011, 8: 79-88.
[6] 萧树东,刘文忠,胡品律,等.短程三联疗法根除幽门螺旋杆菌的多中心临床研究[J].胃肠病学,2000,5(1):14-18.
[7] 刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].中华消化杂志,2012,32(10):655-661.
[8] M alfertheiner P, Megraud F, O ’Morain CA , et a1.Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Repoa[J].Gut,2012,61(5):646-664.
[9] Zullo A, Lerardi E, Hassan C, et al. Furazolidone-based therapies for Helicobacter pylori infection:A pooled date-analysis[J]. Saudi J Gastroenterol, 2012, 18:11-17., 百拇医药(李永宇 陈梅花)